LDLR and familial hyperaldosteronism: Here, we report the first models of patient-specific FH-iPSCs with a homozygous null LDLR mutation and corrected counterparts via CRISPR/Cas9-mediated targeted insertion of an LDLR expression cassette at the safe harbor adeno-associated virus integration site (AAVS1).